Literature DB >> 12646858

A novel attenuated replication-competent adenovirus for melanoma therapy.

I Peter1, C Graf, R Dummer, W Schaffner, U F Greber, S Hemmi.   

Abstract

To generate a replication-competent adenovirus (Ad) with specificity for melanoma, we constructed a tissue-specific promoter restricting E1A expression to melanoma cells. The combination of four copies of a mouse tyrosinase enhancer element (TE) fused to the human tyrosinase promoter (TP) yielded up to 2000-fold higher luciferase reporter activity in tyrosinase-expressing melanoma cells than in nonmelanoma cells. Insertion of the composite TETP construct upstream of the E1A gene was combined with deleting as far as possible the intertwined endogenous Ad enhancer/promoter (EP). The resulting AdDeltaEP-TETP vector, also deleted for the E3 region, was found to replicate in tyrosinase-positive melanoma cells, such as SK-Mel23 as efficiently as wild-type Ad5, but at a more than 50-fold reduced level in nonmelanoma tumour cells and primary human cells. Injection of AdDeltaEP-TETP into xenotransplanted melanomas, but not into HeLa-derived tumours led to long-lasting tumour regression in nude mice. This AdDeltaEP-TETP virus might be useful for the treatment of accessible lesions in advanced melanoma patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12646858     DOI: 10.1038/sj.gt.3301940

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  5 in total

1.  Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro.

Authors:  Alessandra Curioni Fontecedro; Verena Lutschg; Ossia Eichhoff; Reinhard Dummer; Urs F Greber; Silvio Hemmi
Journal:  Virol J       Date:  2010-07-29       Impact factor: 4.099

Review 2.  Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer.

Authors:  Dirk M Nettelbeck
Journal:  J Mol Med (Berl)       Date:  2007-12-19       Impact factor: 4.599

3.  Promoters with cancer cell-specific activity for melanoma gene therapy.

Authors:  V V Pleshkan; I V Alekseenko; M V Zinovyeva; T V Vinogradova; E D Sverdlov
Journal:  Acta Naturae       Date:  2011-04       Impact factor: 1.845

4.  Small-size recombinant adenoviral hexon protein fragments for the production of virus-type specific antibodies.

Authors:  Martin Pacesa; Rodinde Hendrickx; Manuela Bieri; Justin W Flatt; Urs F Greber; Silvio Hemmi
Journal:  Virol J       Date:  2017-08-18       Impact factor: 4.099

5.  Prodrug converting enzyme gene delivery by L. monocytogenes.

Authors:  Jochen Stritzker; Sabine Pilgrim; Aladar A Szalay; Werner Goebel
Journal:  BMC Cancer       Date:  2008-04-10       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.